Advertisement

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David A. Hyman, MD, JD, on Inclusive Shared Savings

Peter Clark, MA, MD, FRCP: A Payer Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Sep
24
Today In Oncology
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
Trastuzumab Rezetecan Improves Progression-Free Survival in Chemotherapy-Refractory HER2-Positive Advanced Colorectal Cancer
SUO/AUA Updates Guidelines for Non-Muscle Invasive Bladder Cancer
Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma
Germline EGFR T790M Associated With Significant Lung Cancer Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo